We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nektar, ImaginAb Enter Into Immuno-Oncology Collaboration
Read MoreHide Full Article
Nektar Therapeutics (NKTR - Free Report) has entered into a non-exclusive license and clinical trial collaboration with privately-held ImaginAb Inc. to support its immuno-oncology pipeline. The deal will allow Nektar to use ImaginAb’s CD8 ImmunoPET technology, which measures the density and distribution of tumor CD8+ T cells in cancer patients.
ImaginAb’s technology will allow Nektar to get a whole-body view of immune system activity without using any invasive procedures on patients. This, in turn, will improve the company’s understanding and help it rationally develop new immunotherapies.
The CD8 ImmunoPET technology can measure CD8+ T cells in multiple tissues, including all target and non-target tumor lesions, simultaneously. Notably, Nektar’s immuno-oncology pipeline consists of candidates that work by targeting CD8+ T cells. For the immuno-oncology therapies, this biomarker will potentially help expedite the development process.
However, Nektara and ImaginAb did not disclose the financial terms of the agreement.
In the past six months, shares of Nektar have lost 45.8% compared with the industry’s 20.6% decline.
Nektar is also developing several immuno-oncology candidates, with NKTR-214 being a primary candidate among them.
Earlier, the company had entered into collaborations to develop NKTR-214 in combination with other therapies.
In November 2018, the company entered into clinical collaboration with Pfizer (PFE - Free Report) to develop doublet or triplet combination therapies of NKTR-214 in several cancer indications, including metastatic castration-resistant prostate cancer and squamous cell carcinoma of the head and neck.
Additionally, it has a collaboration with Bristol-Myers (BMY - Free Report) to evaluate NKTR-214 in combination with Bristol-Myers’ Opdivo alone or with Yervoy in more than 20 indications. In September 2018, Nektar and partner, Bristol-Myers, initiated a phase III study to evaluate NKTR-214 plus Opdivo for treating previously untreated unresectable or metastatic melanoma.
Nektar’s co-development collaboration with Eli Lilly (LLY - Free Report) to develop another immuno-oncology candidate, NKTR-358, is also noteworthy.
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Nektar, ImaginAb Enter Into Immuno-Oncology Collaboration
Nektar Therapeutics (NKTR - Free Report) has entered into a non-exclusive license and clinical trial collaboration with privately-held ImaginAb Inc. to support its immuno-oncology pipeline. The deal will allow Nektar to use ImaginAb’s CD8 ImmunoPET technology, which measures the density and distribution of tumor CD8+ T cells in cancer patients.
ImaginAb’s technology will allow Nektar to get a whole-body view of immune system activity without using any invasive procedures on patients. This, in turn, will improve the company’s understanding and help it rationally develop new immunotherapies.
The CD8 ImmunoPET technology can measure CD8+ T cells in multiple tissues, including all target and non-target tumor lesions, simultaneously. Notably, Nektar’s immuno-oncology pipeline consists of candidates that work by targeting CD8+ T cells. For the immuno-oncology therapies, this biomarker will potentially help expedite the development process.
However, Nektara and ImaginAb did not disclose the financial terms of the agreement.
In the past six months, shares of Nektar have lost 45.8% compared with the industry’s 20.6% decline.
Nektar is also developing several immuno-oncology candidates, with NKTR-214 being a primary candidate among them.
Earlier, the company had entered into collaborations to develop NKTR-214 in combination with other therapies.
In November 2018, the company entered into clinical collaboration with Pfizer (PFE - Free Report) to develop doublet or triplet combination therapies of NKTR-214 in several cancer indications, including metastatic castration-resistant prostate cancer and squamous cell carcinoma of the head and neck.
Additionally, it has a collaboration with Bristol-Myers (BMY - Free Report) to evaluate NKTR-214 in combination with Bristol-Myers’ Opdivo alone or with Yervoy in more than 20 indications. In September 2018, Nektar and partner, Bristol-Myers, initiated a phase III study to evaluate NKTR-214 plus Opdivo for treating previously untreated unresectable or metastatic melanoma.
Nektar’s co-development collaboration with Eli Lilly (LLY - Free Report) to develop another immuno-oncology candidate, NKTR-358, is also noteworthy.
Nektar Therapeutics Price
Nektar Therapeutics Price | Nektar Therapeutics Quote
Zacks Rank
Nektar currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>